Hypermethylation of hMLH1, HPP1, p14(ARF), p16(INK4A) and APC in primary adenocarcinomas of the small bowel

International Journal of Cancer. Journal International Du Cancer
Björn L D M BrücherM Sarbia

Abstract

Small bowel adenocarcinoma (SB-AC) is a very rare tumor entity. Epigenetic alterations, including hypermethylation of DNA mismatch repair genes and tumor suppressor genes, seem to be important for carcinogenesis in tumors of the gastrointestinal tract, but have not yet been investigated in SB-AC. In the current study, the prevalence of hypermethylation in a panel of genes involved in gastrointestinal carcinogenesis (hMLH1, HPP1, p14(ARF), p16(INK4A), APC) was determined in a series of SB-AC. Paraffin-embedded tumor samples from 56 patients with SB-AC who underwent surgical resection between January 1985 and December 2003 were investigated for hypermethylation by means of methylation-specific real-time PCR, and compared with our findings in a previously investigated series of 50 gastric adenocarcinomas. In comparison with adenocarcinomas of the stomach, SB-AC revealed a significantly higher rate of hypermethylation of HPP1 (86% versus 54%, p = 0.0003), p16(INK4A) (32% versus 10%, p = 0.0006), and a significantly lower rate of hypermethylation of APC (48% versus 84%, p = 0.0001). Hypermethylation of hMLH1 and p14(ARF) was present in 23% and 9% of SB-AC, respectively. Locally advanced tumor categories (pT3/4) showed a higher rate ...Continue Reading

References

Aug 1, 1992·Digestive Diseases and Sciences·B A Lashner
Jan 1, 1991·British Journal of Cancer·R K RossB E Henderson
Mar 4, 1997·International Journal of Cancer. Journal International Du Cancer·A H WuT M Mack
Dec 9, 1998·Digestive Surgery·B L BrücherJ R Siewert
Feb 13, 1999·International Journal of Cancer. Journal International Du Cancer·M SarbiaH E Gabbert
Nov 5, 1999·Seminars in Cancer Biology·J G Herman
Jul 14, 2001·ANZ Journal of Surgery·R R HutchinsS J Snooks
Aug 19, 2003·Seminars in Surgical Oncology·Leslie H Sobin
Apr 8, 2004·International Journal of Cancer. Journal International Du Cancer·Helene GeddertMario Sarbia
Jun 16, 2004·International Journal of Cancer. Journal International Du Cancer·Mario SarbiaHelmut Erich Gabbert
Sep 28, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Essel DulaimiPaul Cairns
Oct 1, 2004·Journal of Cell Science·Inke Näthke

❮ Previous
Next ❯

Citations

Feb 12, 2008·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Perumal Vivekanandan, Michael Torbenson
Sep 18, 2007·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Marloes BerkhoutJudith W M Jeuken
May 19, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J C HaanB Ylstra
Jan 1, 2006·Hereditary Cancer in Clinical Practice·David Mossman, Rodney J Scott
Jul 5, 2006·Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology·Sa Kan YooYasuhiro Minami
Jul 1, 2017·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Alessandro VanoliEnrico Solcia
May 8, 2014·Expert Review of Anticancer Therapy·Katsuhiro Hanada, David Y Graham
Oct 31, 2018·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Joon Seon SongSeung-Mo Hong
Feb 25, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Begoña DiosdadoGerrit A Meijer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.